|Table of Contents|

Analysis of factors associated with pathological complete remission after neoadjuvant chemotherapy for breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
86-90
Research Field:
Publishing date:

Info

Title:
Analysis of factors associated with pathological complete remission after neoadjuvant chemotherapy for breast cancer
Author(s):
SHANG Lingmin; MENG Xiangyu; WU Yang; CHENG Shaoqiang
Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.
Keywords:
metabolic syndrome; breast cancer; neoadjuvant chemotherapy; pathological complete response
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.01.015
Abstract:
Objective:To investigate the relationship between metabolic syndrome(MS) and pathological complete response(pCR) in breast cancer patients received neoadjuvant chemotherapy(NAC).Methods:The clinicopathological data of 526 female breast cancer patients who underwent surgery after NAC in the Harbin Medical University Cancer Hospital from January 2014 to June 2020 were collected.According to the MS diagnostic criteria,patients were divided into MS group(n=99),and non-MS group(n=427).Univariate and multivariate analysis of the relationship between MS and pCR was performed with Logistic regression model.Results:105 patients achieved pCR after NAC,including 10 patients in the MS group and 95 patients in the non-MS group.Univariate analysis showed that compared with the MS group,the non-MS group was more likely to reach pCR(P=0.008),and the hormone receptor(HR) negative,human epidermal growt factor receptor-2(HER-2) positive,Ki-67>14% patients were more likely to achieve pCR(P＜0.001,P＜0.001,P=0.002).Multivariate analysis showed that compared with HR negative patients,HR positive patients were more difficult to reach pCR(P＜0.001).Compared with HER-2 negative patients,HER-2 positive patients had higher pCR rate(P=0.033).Compared with non-MS patients,the pCR rate was lower in MS patients(P=0.041).Subgroup analysis showed that HR negative patients in the non-MS group were more likely to achieve pCR(P＜0.001).Conclusion:HR status,HER-2 status and MS are independent predictors of pCR after NAC in breast cancer patients.Breast cancer patients with MS are more difficult to achieve pCR after NAC,and their correlation with long-term prognosis needs further study.

References:

[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2021,71(3):209-249.
[2］SHIEN T,IWATA H.Adjuvant and neoadjuvant therapy for breast cancer ［J］.Japanese Journal of Clinical Oncology,2020,50(3):225-229.
[3］WANG H,MAO X.Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer ［J］.Drug Des Devel Ther,2020,14:2423-2433.
[4］USISKIN I,LI F,IRWIN ML,et al.Association between pre-diagnosis BMI,physical activity,pathologic complete response,and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer ［J］.Breast Cancer,2019,26(6):719-728.
[5］ARICI S,GEREDELI C,SECMELER S,et al.The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy ［J］.Curr Probl Cancer,2020,44(1):100485.
[6］LEMIEUX I,DESPRES JP.Metabolic syndrome:Past,present and future ［J］.Nutrients,2020,12(11):3501-3512.
[7］LI R,LI W,LUN Z,et al.Prevalence of metabolic syndrome in Mainland China:a meta-analysis of published studies ［J］.BMC Public Health,2016,16:296-299.
[8］ESPOSITO K,CHIODINI P,COLAO A,et al.Metabolic syndrome and risk of cancer:a systematic review and meta-analysis ［J］.2012,35(11):2402-2411.
[9］中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议 ［J］.中国糖尿病杂志,2004,12(3):156-161. Metabolic Syndrome Research Collaborative Group of Chinese Diabetes Society.Chinese diabetes society's suggestions on metabolic syndrome［J］.Chin J Diabetes,2004,12(3):156-161.
[10］UZUNLULU M,TELCI CAKLILI O,OGUZ A.Association between metabolic syndrome and cancer ［J］.Ann Nutr Metab,2016,68(3):173-179.
[11］ZHANG J,WU H,WANG R.Metabolic syndrome and esophageal cancer risk:a systematic review and metaanalysis ［J］.Diabetol Metab Syndr,2021,13(1):8-9.
[12］CONTEDUCA V,CAFFO O,GALLI L,et al.Association among metabolic syndrome,inflammation,and survival in prostate cancer ［J］.Urol Oncol,2018,36(5):240.e1-240.e11.
[13］BUONO G,CRISPO A,GIULIANO M,et al.Metabolic syndrome and early stage breast cancer outcome:results from a prospective observational study ［J］.Breast Cancer Res Treat,2020,182(2):401-409.
[14］DIELI-CONWRIGHT CM,WONG L,WALIANY S,et al.An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy ［J］.Cancer,2016,122(17):2646-2653.
[15］GOMES SL,BOBBY Z,GANESAN P,et al.Metabolic syndrome and its related biochemical derangements in breast cancer patients who received neoadjuvant chemotherapy:A study from a tertiary care oncology centre from Puducherry,South India ［J］.Diabetes Metab Syndr,2021,15(3):975-980.
[16］ROBERTS CK,HEVENER AL,BARNARD RJ.Metabolic syndrome and insulin resistance:underlying causes and modification by exercise training ［J］.Compr Physiol,2013,3(1):1-58.
[17］DONG S,WANG Z,SHEN K,et al.Metabolic syndrome and breast cancer:Prevalence,treatment response,and prognosis ［J］.Frontiers in Oncology,2021,11:629-666.
[18]吴玉团，罗清清，孔令泉，等.代谢综合征与乳腺癌的关系［J］.现代肿瘤医学，2016,24（22）:3073-3077. WU Yutuan,LUO Qingqing,KONG Lingquan,et al.The relationship between metabolic syndrome and breast cancer［J］.Modern Oncology,2016,24（22）:3073-3077.
[19］GLUVIC Z,ZARIC B,RESANOVIC I,et al.Link between metabolic syndrome and insulin resistance ［J］.Current Vascular Pharmacology,2017,15(1):30-39.
[20］CHEN Y,WEN YY,LI ZR,et al.The molecular mechanisms between metabolic syndrome and breast cancer ［J］.Biochem Biophys Res Commun,2016,471(4):391-395.
[21］DIBABA DT,OGUNSINA K,BRAITHWAITE D,et al.Metabolic syndrome and risk of breast cancer mortality by menopause,obesity,and subtype ［J］.Breast Cancer Research and Treatment,2018,174(1):209-218.
[22］STEFANSKA A,BERGMANN K,SYPNIEWSKA G.Metabolic syndrome and menopause:Pathophysiology,clinical and diagnostic significance ［J］.Adv Clin Chem,2015,72:1-75.
[23］KABAT GC,KIM MY,LEE JS,et al.Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women ［J］.Cancer Epidemiol Biomarkers Prev,2017,26(12):1730-1735.

Memo

Memo:
-
Last Update: 2022-11-30